(PharmaNewsWire.Com, November 03, 2017 ) RNA interference is a process in which RNA inhibits the gene expression, by degrading mRNA molecules. It is also called Gene silencing. Recently, we are sending artificial drugs to carry out these functions and that process is called RNAi Drug Delivery.
The growth of this method is started from last 15 years before that this method was applied only to the plants. Right now, Researchers are doing various types of experiments to minimize the side effects of drugs and to invent new types of drugs.
Few factors like increasing incidence of chronic diseases like cancer and cardiovascular diseases, and innovative Applications of drug delivery market are driving this market. In addition, Research carried out in RNA Therapeutic field has also fueled the growth in Asia Pacific RNA Drug Delivery Market. But, High investments and stringent Regulations are some of the major restraints to this market. Targeted Delivery of RNAi Drugs is the key challenge faced by the market. Increasing investments by key players of this market is driving this market’s growth.
Asia-Pacific RNAi Drug Delivery market is segmented based on Drug Delivery and Therapeutic Application. Based on Drug Delivery, this market is further segmented into pulmonary drug delivery technology, aptamer drug delivery technology, nucleic acid drug delivery technology and nanoparticle drug delivery technology. Based on Therapeutic Application, the market is further segmented into cardiology, metabolic disorders, oncology, ophthalmology, infectious diseases and neurology.
Based on Geography, this market is further segmented in to India, China, Japan, Australia and South Korea. This region has the highest CAGR because of increased investments by key players in this region.
Key players in this region are Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Access Pharmaceuticals Inc., Sirnaomics Inc., Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp., Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Marina Biotech Inc., Tacere Therapeutics Inc., and PhaseRx Inc.
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
